AC Immune SA (ACIU)
2.925
+0.06
(+2.27%)
USD |
NASDAQ |
Aug 25, 14:03
AC Immune Enterprise Value : 172.21M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 172.21M |
| August 21, 2026 | 175.85M |
| August 20, 2026 | 152.17M |
| August 19, 2026 | 146.70M |
| August 18, 2026 | 145.79M |
| August 17, 2026 | 142.15M |
| August 14, 2026 | 138.50M |
| August 13, 2026 | 145.79M |
| August 12, 2026 | 150.35M |
| August 11, 2026 | 143.06M |
| August 10, 2026 | 119.37M |
| August 07, 2026 | 126.66M |
| August 06, 2026 | 123.02M |
| August 05, 2026 | 120.28M |
| August 04, 2026 | 118.46M |
| August 03, 2026 | 113.91M |
| July 31, 2026 | 111.17M |
| July 30, 2026 | 127.57M |
| July 29, 2026 | 118.46M |
| July 28, 2026 | 123.02M |
| July 27, 2026 | 121.19M |
| July 24, 2026 | 114.82M |
| July 23, 2026 | 115.73M |
| July 22, 2026 | 118.46M |
| July 21, 2026 | 121.19M |
| Date | Value |
|---|---|
| July 20, 2026 | 116.64M |
| July 17, 2026 | 112.08M |
| July 16, 2026 | 110.26M |
| July 15, 2026 | 126.66M |
| July 14, 2026 | 131.22M |
| July 13, 2026 | 134.86M |
| July 10, 2026 | 129.39M |
| July 09, 2026 | 148.52M |
| July 08, 2026 | 141.24M |
| July 07, 2026 | 143.06M |
| July 06, 2026 | 140.33M |
| July 02, 2026 | 140.33M |
| July 01, 2026 | 128.48M |
| June 30, 2026 | 128.48M |
| June 29, 2026 | 154.00M |
| June 26, 2026 | 144.91M |
| June 25, 2026 | 134.91M |
| June 24, 2026 | 143.09M |
| June 23, 2026 | 134.91M |
| June 22, 2026 | 139.46M |
| June 18, 2026 | 130.37M |
| June 17, 2026 | 124.92M |
| June 16, 2026 | 127.64M |
| June 15, 2026 | 124.92M |
| June 12, 2026 | 122.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 35.54B |
| CRISPR Therapeutics AG | 3.936B |
| Idorsia Ltd. | 3.462B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.371M |
| Revenue (Quarterly) | 19.12M |
| Total Expenses (Quarterly) | 16.75M |
| EPS Diluted (Quarterly) | 0.026 |
| Profit Margin (Quarterly) | 12.40% |
| Earnings Yield | -19.01% |
| Normalized Earnings Yield | -18.87 |